Meriofert

Follicle-Stimulating Hormone, Luteinising Hormone, the active ingredient in Meriofert, is a gonadotropin presented as an injectable solution for intramuscular or subcutaneous use. It is used to treat infertility caused by anovulation and to support controlled ovarian stimulation in assisted reproductive technologies for women of reproductive age.

GNH USA supplies Meriofert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert is a gonadotropin that acts on the ovarian hormonal axis to facilitate follicular growth and ovulation.

- Anovulatory infertility: induces follicular development and ovulation in women who do not ovulate spontaneously. - Assisted reproductive technology cycles: provides controlled ovarian stimulation to obtain multiple mature oocytes for IVF or ICSI. - Hypogonadotropic hypogonadism: supplies exogenous FSH and LH to stimulate ovarian function in patients with deficient endogenous gonadotropins.

Common Side Effects: - Injection site pain or erythema. - Mild abdominal or pelvic discomfort. - Headache. - Nausea or mild gastrointestinal upset. - Transient ovarian cyst formation. - Mild ovarian hyperstimulation (limited to mild ovarian enlargement).

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome (OHSS) with ascites or thromboembolic complications. - Multiple pregnancy (twins or higher order). - Allergic reactions including anaphylaxis. - Ectopic pregnancy. - Thromboembolic events such as deep vein thrombosis. - Severe ovarian cyst rupture with intra‑abdominal bleeding.

Meriofert should be used under close medical supervision with individualized dosing. - Monitor ovarian response: perform ultrasound and estradiol monitoring to adjust dose. - Avoid in uncontrolled thyroid disease: thyroid status can affect gonadotropin response. - Caution in estrogen‑sensitive tumors: assess risk before initiating therapy. - Do not use during pregnancy: the drug is intended for pre‑conception ovarian stimulation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Major Interactions (Avoid): - Estrogen‑containing contraceptives: may blunt the intended ovarian response. - High‑dose glucocorticoids: can interfere with gonadotropin activity. - Anticoagulant therapy: increased risk of ovarian cyst rupture.

Moderate Interactions (Monitor Closely): - Thyroid hormone replacement: may require dose adjustment of gonadotropins. - GnRH agonists/antagonists: timing must be coordinated to avoid overstimulation. - Dopamine agonists (e.g., bromocriptine): may affect prolactin‑mediated ovarian function.